NCT03893019View on ClinicalTrials.gov

MB-CART20.1 Melanoma

EARLY_PHASE1TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

March 8, 2019

Primary Completion Date

January 30, 2023

Study Completion Date

January 30, 2023

Conditions
Melanoma (Skin)
Interventions
BIOLOGICAL

MB-CART20.1

MB-CART20.1 consists of autologous CD20 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells targeting CD20.positive tumor cells

Trial Locations (1)

50937

University Hospital of Cologne - Clinic for Internal Medicine I, Cologne

Sponsors
All Listed Sponsors
collaborator

DLR German Aerospace Center

OTHER

lead

Miltenyi Biomedicine GmbH

INDUSTRY